From surveillance data of patients hospitalized with laboratory-confirmed influenza in the United States during the 2015-2016 through 2018-2019 seasons, initiation of antiviral treatment increased from 86% to 94%, with increases seen across all age groups. However, 62% started therapy ≥3 days after illness onset, driven by late presentation to care.
Keywords: antiviral; baloxavir; hospital; influenza; oseltamivir; treatment delay.
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.